Managing Depression during Hepatitis C Treatment
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Objective: The prevalence of hepatitis C virus (HCV) infection in Canada is estimated to be 1% and expected to increase during the next decade. Mental illness, particularly depression, is common among HCV-infected patients and remains an obstacle to interferon-alpha (IFN-α) treatment. We summarize the risk factors for interferon-α–induced major depressive disorder (IFN-α–MDD) in HCV patients and the evidence for antidepressant prophylaxis and symptomatic antidepressant treatment of depression. Methods: We searched MEDLINE, EMBASE, and CINAHL for randomized controlled or quasi-experimental trials evaluating antidepressant prophylactic and symptomatic treatment approaches for depression emerging during IFN-α treatment. Manual searches of references listed in review articles, case series, and anecdotal reports supplemented our literature search. Results: A total of 9 trials involving prophylactic and symptomatic treatment approaches for IFN-α–MDD are summarized in our review. Antidepressant pretreatment is beneficial for patients with elevated baseline depressive symptoms and a preexisting history of IFN-α–MDD. Although limited evidence exists for several antidepressant agents, much of the evidence suggests that selective serotonin reuptake inhibitors (SSRIs) are safe and efficacious in treating depressive symptoms secondary to IFN-α therapy. Conclusion: Both antidepressant pretreatment and symptomatic treatment are viable strategies for treating IFN-α–MDD. Improved treatment outcomes and early identification of depression during HCV treatment can be achieved using an integrated medical and mental health treatment approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
Capuron, L. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00407-9 · Cited by 797
Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness
(2001) · American Journal of Public Health · doi:10.2105/ajph.91.1.31 · Cited by 589
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
Wichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpé, S., & Maes, M. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001600 · Cited by 445 · cited 13×
“Animal studies have shown an upregulation of 5-HT transporter messenger ribonucleic acid in response to IFN- ; however, human studies of HCV patients have failed to replicate these findings.48,49 The overlap between the concept of cytokine-induced sickness behaviour, which is defined as anhedonia, anorexia, and decrea…”
BackgroundInfluentialBonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Verkerk, R., Meltzer, H., & Maes, M. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00014 · Cited by 437
Psychiatric Complications of Long-term Interferon Alfa Therapy
Renault, P. F. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370090055011 · Cited by 413 · cited 1×
“Despite early studies identifying high-dose IFN- as a risk factor for IFN- –MDD in HCV patients, several studies have refuted this finding.(26,43,44)”
ResultDepression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors
Golden, J., O'Dwyer, A. M., & Conroy, R. M. (2005) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2005.06.006 · Cited by 211
Cytokines, “depression due to a general medical condition”, and antidepressant drugs
Yirmiya, R., Weidenfeld, J., Pollak, Y., Morag, M., Morag, A., Avitsur, R., Barak, O., Reichenberg, A., Cohen, E., Shavit, Y., et al. (1999) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-585-37970-8_16 · Cited by 208 · cited 13×
“Animal studies have shown an upregulation of 5-HT transporter messenger ribonucleic acid in response to IFN- ; however, human studies of HCV patients have failed to replicate these findings.48,49 The overlap between the concept of cytokine-induced sickness behaviour, which is defined as anhedonia, anorexia, and decrea…”
BackgroundInfluentialCapuron, L., & Ravaud, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401716 · Cited by 169
RAISON, C. L., WOOLWINE, B. J., DEMETRASHVILI, M. F., BORISOV, A. S., WEINREIB, R., STAAB, J. P., ZAJECKA, J. M., BRUNO, C. J., HENDERSON, M. A., REINUS, J. F., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03316.x · Cited by 142
Horikawa, N., Yamazaki, T., Izumi, N., & Uchihara, M. (2003) · General Hospital Psychiatry · doi:10.1016/s0163-8343(02)00239-6 · Cited by 140 · cited 2×
“Weak dopamine antagonists, such as amisulpride, sulpiride, and levosulpiride, possess antidepressant properties and may be beneficial in managing depressed HCV patients during immunotherapy.(17,76) Martin et al(89) showed a small but statistically significant change in IFN- –induced fatigue following treatment with mo…”
BackgroundSuicidal ideation during interferon-α2b and ribavirin treatment of patients with chronic hepatitis C
Dieperink, E., Ho, S. B., Tetrick, L., Thuras, P., Dua, K., & Willenbring, M. L. (2004) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2004.01.003 · Cited by 106
Depression following pegylated interferon-alpha: Characteristics and vulnerability
Lotrich, F. E., Rabinovitz, M., Gironda, P., & Pollock, B. G. (2007) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2007.05.013 · Cited by 100 · cited 1×
“In 2 studies of 23 and 36 HCV patients receiving IFN- , baseline BDI, and baseline HDRS scores were the best predictors of depressive symptoms emerging as quickly as 1 month after starting IFN- treatment.(35,36) The emergence of neurovegetative symptoms as early as the first week of immunotherapy may also confer an in…”
BackgroundCarta, M. G., Hardoy, M., Garofalo, A., Pisano, E., Nonnoi, V., Intilla, G., Serra, G., Balestrieri, C., Chessa, L., Cauli, C., et al. (2007) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-3-22 · Cited by 91
Matthews, A. M., Huckans, M. S., Blackwell, A. D., & Hauser, P. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00472.x · Cited by 40
Cited by
The role of inflammatory cytokines in suicidal behavior: A systematic review
Serafini, G., Pompili, M., Elena Seretti, M., Stefani, H., Palermo, M., Coryell, W., & Girardi, P. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.06.002 · Cited by 151
Fragoso, Y. D., Frota, E. R. C., Lopes, J. S., Noal, J. S., Giacomo, M. C., Gomes, S., Gonçalves, M. V. M., da Gama, P. D., & Finkelsztejn, A. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181f8d513 · Cited by 116
Martino, M., Rocchi, G., Escelsior, A., & Fornaro, M. (2012) · Current Neuropharmacology · doi:10.2174/157015912800604542 · Cited by 111
“SSRIs, particularly paroxetine, are recommended in the treatment of depression in course of HCV infection [437, 438].”
Background
Metadata
- Authors
- Sockalingam, S., & Abbey, S. E.
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2009-09
- Volume
- 54
- Issue
- 9
- Pages
- 614-625
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- OpenAlex
- W3884175
- Cited by
- 60
- References
- 16
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.